The Skill to Heal. The Heart to Care.

Phone: 505.842.8171

dotAfter Hours: 505.857.3877

dotPharmacy: 505.822.3911




Latest Cancer News

Breast Cancer Research and Treatment Publishes Oncotype DX(R) DCIS Score(TM) Study Conducted in Canada (08-27-2015)

Genomic Health, Inc. (Nasdaq: GHDX) announced that Breast Cancer Research and Treatment published results from a second large clinical validation study of Oncotype DX® in patients with stage 0 breast cancer, also known as DCIS (Ductal Carcinoma In Situ).... Continue Reading

Patients Rising, Launched to Fight for Access to Vital Therapies and Services for Patients with Life-Threatening Diseases (08-25-2015)

Patient advocacy veterans Jonathan and Terry Wilcox today announced the launch of a new not-for-profit organization, Patients Rising. This patient advocacy organization will educate, advocate and communicate the importance of access to vital therapies... Continue Reading

Understanding Precision Cancer Medicine (08-25-2015)

Precision cancer medicine is an evolving concept in cancer care that aims to leverage new genomic information about a specific cancer to more precisely target treatment. Precision medicine seeks to define the genomic alterations that are driving a specific... Continue Reading

XBiotech Completes Enrollment for Xilonix™ Phase III Registration Study in Europe, US Trial Ongoing (08-24-2015)

XBiotech has announced that it has completed enrollment of the Company’s pivotal, randomized double-blinded placebo controlled Phase III study in Europe of Xilonix™ for the treatment of advanced colorectal cancer. The US based trial is ongoing at... Continue Reading

Two-drug combination boosts survival in metastatic prostate cancer (08-17-2015)

Newly diagnosed patients with metastatic, hormone-sensitive prostate cancer gained a dramatic survival benefit when started on two drugs simultaneously, rather than delaying the second drug until the cancer began to worsen, according to results of a clinical... Continue Reading

Food and Drug Administration approves Odomzo for treatment of basal cell carcinoma (08-13-2015)

The U. S. Food and Drug Administration approved Odomzo® (sonidegib, formerly LDE225) for the treatment of patients with locally advanced basal cell carcinoma (laBCC) that has recurred following surgery or radiation therapy, or those who are not candidates... Continue Reading

FDA Designates Breakthrough Therapy Designation for Azedra in Pheochromocytoma and Paraganglioma (08-12-2015)

The U.S. Food and Drug Administration (FDA) has designated Azedra as a Breakthrough Therapy for the treatment of patients with iobenguane-avid metastatic or recurrent pheochromocytoma and paraganglioma. Azedra is currently being evaluated in a pivotal... Continue Reading

Vectibix® Improves Survival in Patients with Wild-Type KRAS Metastatic Colorectal Cancer after Progression on Chemotherapy (08-11-2015)

  Vectibix® (panitumumab) appears to improve overall survival among patients with wild-type KRAS metastatic colorectal cancer that has progressed on or following chemotherapy. A Phase III trial of Vectibix is currently underway, but researchers... Continue Reading

Afinitor® Promising in Neuroendocrine Tumors Originating in Gastrointestinal Tract or Lungs (08-10-2015)

The drug Afinitor® (everolimus) is currently be studied in a Phase III clinical trial for patients with nonfunctional neuroendocrine tumors (NET) of the gastrointestinal (GI) tract or lungs. The trial is ongoing, but findings so far are promising: patients... Continue Reading

Protein Circulating in Blood Could Be Key to Early Diagnosis of Pancreatic Cancer (08-6-2015)

Research suggests a promising new way to screen for and detect early pancreatic cancer. Certain proteins that circulate in the blood may help identify patients with this disease, for which there’s currently no reliable screening. These findings were... Continue Reading

Oncotype DX Increases Use of Active Surveillance in Prostate Cancer Patients (08-5-2015)

Genomic Health, Inc. announced that Urology Practice published results from the second clinical utility study of the Oncotype DX® prostate cancer test, showing that incorporation of the test’s Genomic Prostate Score (GPS) in treatment planning... Continue Reading

Role of Tumor Size and Estrogen-Receptor Status in Decline in Breast Cancer Deaths (08-4-2015)

In light of a general decline in breast cancer death since the late 1980s, research has now turned to how type and stage of disease affect survival among different women. These findings, which considered tumor size and estrogen-receptor (ER) status,... Continue Reading

Next Page »